Taysha Gene Therapies, Inc.

Healthcare · Biotechnology · United States

Last price 4.22 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.38B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-...